Therapeutic Response

BRCA2 pathogenic variants and HER2-negative status confers therapeutic sensitivity to Talazoparib in patients with Invasive Breast Carcinoma.

Statements

Source and description

Talzenna (talazoparib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to talazoparib for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. The product label states to select patients for therapy based on an FDA-approved companion diagnostic for Talazoparib.